Abbisko Therapeutics Co, Ltd

This phase 2 trial tests a combination of two drugs, ABSK043 and glecirasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The study will enroll 86 participants to see if the combination is safe and can shrink tumors. It i…

This early-stage study tests a new drug called ABSK-011 in about 200 people with advanced solid tumors, especially liver cancer that has not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Pa…

This early-stage study tests an experimental pill called ABSK021 in people with advanced solid tumors (including a rare joint tumor called TGCT) who have run out of standard options. The main goal is to check safety and find the best dose, while also seeing if the drug can shrink…

This study tests a new drug called ABSK141 in people with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors. About 401 adults with cancers like colorectal, lung, or pancreatic cancer will…

This study tests a new drug called ABSK-011 for people with advanced liver cancer that has not responded to prior treatments. The drug targets a specific protein (FGF19) found in some tumors. About 141 participants will receive either ABSK-011 plus standard care or a placebo plus…

This early-stage trial tests an experimental oral drug called ABSK131 in people with advanced solid tumors that have lost a gene called MTAP. The study aims to find a safe dose and see if the drug can shrink tumors. About 266 participants will receive the drug daily, and research…

This study follows 260 children with achondroplasia (ages 2.5 to 11) for up to 2 years to collect data on growth, medical complications, and quality of life. No treatment is given—it is purely observational to better understand the condition's natural course.